CLDX
Celldex Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-25
Figures on this page computed 2026-11-08 12:48 UTC
Last close
29.87USD
Market data, 2026-11-06
Except where said otherwise: 10-K for 2025, filed 2026-02-25
n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-019652
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-25
-57.4%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-019652
- Reported in
- USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-08-06
-16748.0%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-019652
- Reported in
- USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
-13829.1%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-019652
- Reported in
- USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
0.004Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-019652
- Reported in
- USD
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-08-06
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Growth is the furthest below its sector's middle: 0.12 against 0.50 on the market's range.
- Growth-26.9%12 of 100, below its sector
- Returns on capital-57.4%13 of 100, below its sector
- Margins87.1%25 of 100, below its sector
- Price3.8x13 of 100, below its sector
- Safety0.00494 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Six questions
lens 5 of 9Six questions
0 yes of 4 answered- 1Does it earn money?no
net margin, read above 0.
- 2Can it pay what it owes?Not known
interest coverage, read above 3. We do not hold that figure for this company.
- 3Is it bigger than five years ago?no
rev growth 5y, read above 0.
- 4Does the profit turn into cash?no
fcf margin, read above 0.
- 5Is it issuing shares?no
share count change yoy, read below 1.
- 6Is it priced under twenty times earnings?Not known
pe ratio, read below 20. We do not hold that figure for this company.
2 of these could not be answered. That is not a no: it is a figure we do not hold, and it is left as what it is.
0 of 4 questions answered yes; 2 could not be answered.
0 of 4 questions answered yes; 2 could not be answered.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-02-25
Does it earn money?-16748.0%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-019652
- Reported in
- USD
Can it pay what it owes?n/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-019652
- Reported in
- USD
Is it bigger than five years ago?-26.9%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-019652
- Reported in
- USD
Does the profit turn into cash?-13829.1%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-019652
- Reported in
- USD
Is it issuing shares?3.1%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-019652
- Reported in
- USD
Is it priced under twenty times earnings?n/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-019652
- Reported in
- USD